

First Clinical Data of Medtronic Drug-Filled Stent Show Positive Outcomes

October 31, 2016 11:00 AM CT



Featured 'First Report' RevElution Trial at TCT Highlights the Potential Benefits of First-of-its-Kind Polymer-Free Technology with Controlled and Sustained Drug Delivery for Rapid Vessel Healing

DUBLIN and WASHINGTON, D.C. - Oct. 31, 2016 - Medtronic plc (NYSE: MDT) unveiled today the first clinical outcomes of its novel Drug-Filled Stent (DFS) from the RevElution Trial at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Also published simultaneously in the *Journal of the American College of Cardiology (JACC): Cardiovascular Intervention*, the polymer-free DFS met its primary endpoint of in-stent late lumen loss at nine months compared to a current-generation drug-eluting stent (DES), and also demonstrated positive clinical outcomes.

The RevElution trial enrolled 101 patients at 14 centers in three countries in two different cohorts measuring outcomes at nine months and 24 months. In the first 50 patients included in the nine-month primary endpoint cohort, the DFS had in-stent late lumen loss of 0.26mm, which was non-inferior to the historical control ($p < 0.001$). In addition, the DFS demonstrated low rates of target lesion failure (2.1 percent) and zero stent thrombosis at nine months.

Optical coherence tomography (OCT) data were reported from two cohorts of patients who were scheduled to receive OCT either at one and nine months (15 patients) or three and nine months (15 patients). In both groups, the DFS showed an early healing profile with the median strut coverage (new cell growth over stent struts) of 91.4 percent and 95.6 percent at one and three months, respectively, and low rates of malapposed struts at one month (0.3 percent) that decreased to 0 percent at nine months. At nine months, the median strut coverage increased to 99.1 percent with no cases of late acquired stent malapposition.

"These early results demonstrate that the controlled and sustained elution of the polymer-free DFS show the potential for rapid healing without inflammation and positive clinical outcomes," said Stephen Worthley, M.D., professor at the Royal Adelaide Hospital in Adelaide, Australia and co-principal investigator of the DFS trial who presented the data at TCT. "In addition, we look forward to better understanding how this technology may potentially impact the duration of dual antiplatelet therapy in some patients."

The DFS builds on the proven Continuous Sinusoid Technology (CST) platform and innovative CoreWire Technology. Introduced with the Resolute Integrity DES, CST is a unique Medtronic method of manufacturing, which involves forming a single strand of wire into a sinusoidal wave to construct a stent, enabling a continuous range of motion, resulting in excellent deliverability and conformability to the vessel wall. CoreWire Technology-introduced with the next generation Resolute Onyx(TM) DES (investigational in the United States) -allows the stent forming wire to have multiple layers with a denser core metal surrounded by a cobalt alloy outer layer for thinner struts and greater deliverability, while offering enhanced radiopacity (i.e., visibility during the procedure) without compromising structural strength.

The DFS features a novel tri-layer wire design. The innermost layer is removed and becomes a lumen continuously coated with drug. The drug (sirolimus) is eluted from the inside of the stent through multiple laser-drilled holes on the abluminal side (outer surface) of the stent. The polymer-free design allows for controlled and sustained drug elution directly into the arterial wall without the adverse vascular effects associated with polymers, such as inflammation due to polymer degradation, flaking or hypersensitivity reactions.

"Today marks a notable milestone in working with interventional cardiologists across the globe to realize the potential of this breakthrough technology, which has the ability to help address unmet clinical needs if the clinical data continues to be positive," said Jason Weidman, vice president and general manager of the Coronary and Renal Denervation business, which is part of the Cardiac and Vascular Group at Medtronic. "Now with the initial clinical outcomes in hand, we look

forward to beginning the path toward commercialization for the drug-filled stent to further advance our innovative coronary portfolio."

The Drug-Filled Stent is available for investigational use only and it is not approved for use outside of clinical studies.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Contacts:

Joey Lomicky
Public Relations
+1-763-526-2494

Ryan Weispfenning
Investor Relations
+1-763-505-4626